North America plays a significant role in the development and adoption of advanced SBS treatment approaches, supported by sophisticated healthcare infrastructure, specialized gastrointestinal care, and increasing awareness of intestinal failure. The US, in particular, benefits from strong pharmaceutical and biotechnology activity, specialized treatment centers, and growing adoption of innovative therapies designed to improve intestinal absorption and reduce dependence on parenteral nutrition. Increasing research and development activities and greater emphasis on personalized patient care are further strengthening the regional outlook.

Growth Outlook and Market Valuation

The global short bowel syndrome market size is projected to reach US$ 2.66 billion by 2034 from US$ 1.69 billion in 2025. The market is anticipated to register a CAGR of 5.16% during the forecast period 2026-2034. According to The Insight Partners, the total addressable market is estimated at approximately US$ 19.73 billion during 2026-2034, highlighting the commercial potential associated with evolving SBS therapies and supportive care solutions.

Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00011653

Rising Disease Burden Supporting Demand

The increasing prevalence of SBS is an important factor supporting demand for effective treatment options. Advances in surgical procedures have improved survival among patients undergoing complex intestinal interventions, but some patients subsequently experience reduced intestinal function. Conditions such as Crohn's disease, intestinal ischemia, bowel obstruction, trauma, and gastrointestinal complications can increase the need for bowel resection and contribute to SBS. As diagnosis improves and more patients receive long-term care, healthcare providers are increasingly seeking therapies that support nutrient absorption, fluid management, gastrointestinal adaptation, and quality of life.

Surgical Advances and Expanding Patient Population

Growth in complex gastrointestinal surgeries is another significant factor influencing demand. Improvements in surgical technology, perioperative management, and intensive care have enabled physicians to treat patients with complicated intestinal conditions more effectively. However, bowel resections may reduce the functional length of the intestine, creating a need for sustained nutritional and pharmaceutical management. This dynamic is encouraging healthcare providers to adopt comprehensive approaches that combine nutritional support, pharmacological treatment, monitoring, and specialized multidisciplinary care. Consequently, rising numbers of patients surviving major intestinal procedures are contributing to a broader pool of individuals requiring SBS management.

Early Diagnosis and Growing Clinical Awareness

Improved awareness among healthcare professionals and patients is creating favorable conditions for earlier identification and treatment of SBS. Enhanced diagnostic capabilities and greater understanding of intestinal failure can help clinicians identify nutritional deficiencies and gastrointestinal complications sooner. Early intervention can support appropriate nutritional strategies and reduce the risk of severe complications. In parallel, patient advocacy initiatives and educational programs are increasing awareness of available treatment options. This trend is particularly important for chronic SBS management, where long-term monitoring and individualized care can significantly influence treatment outcomes.

Short Bowel Syndrome Market Growth

The evolution of pharmacological therapies is becoming a major trend in SBS management. GLP-2-based approaches are attracting significant attention because of their potential to improve intestinal absorption and reduce dependence on parenteral nutrition in appropriate patients. The growing focus on targeted therapies reflects a broader shift toward treatment strategies that address underlying intestinal adaptation rather than relying exclusively on nutritional replacement. Continued research into biologics, intestinal rehabilitation, and patient-specific treatment approaches is expected to support innovation throughout the forecast period. The report segments the market by drug class into glucagon-like peptide, H2 blockers, proton pump inhibitors, and others.

Home-Based Nutritional Support Emerging as a Key Trend

A notable trend is the growing shift from hospital-centered nutritional management toward home-based care. Patients requiring long-term nutritional support can increasingly receive treatment outside traditional inpatient environments through improved infusion pumps, feeding technologies, monitoring systems, and specialized nutritional products. Home-based care can provide greater flexibility while potentially reducing hospital utilization and improving patient convenience. This trend is expected to create opportunities for pharmaceutical companies, medical device manufacturers, nutrition providers, and healthcare services organizations developing solutions specifically designed for chronic SBS management. The movement toward decentralized care is particularly relevant in healthcare systems with established home-care infrastructure.

Personalized Treatment and Multidisciplinary Care

Personalized treatment strategies are gaining importance as healthcare professionals recognize the varying causes, severity, anatomy, nutritional requirements, and treatment responses associated with SBS. Individualized care plans can combine pharmaceutical interventions with dietary management, enteral nutrition, parenteral nutrition, fluid replacement, and continuous clinical monitoring. At the same time, multidisciplinary care models involving gastroenterologists, surgeons, nutrition specialists, nurses, pharmacists, and other healthcare professionals are becoming increasingly important. These coordinated approaches can help address the complex nutritional, metabolic, and gastrointestinal needs of SBS patients while supporting long-term disease management.

Distribution Channels Expanding Patient Access

Distribution infrastructure is also influencing treatment accessibility. The market is segmented into hospital pharmacies, retail pharmacies, and online sales channels. Hospital pharmacies remain important because SBS patients often require specialized therapies and clinical supervision. However, retail and online channels can support continued access to prescribed treatments and nutritional products, particularly for patients receiving long-term care at home. As healthcare systems increasingly emphasize convenience and outpatient treatment, distribution networks capable of supporting home-based therapies are expected to become more strategically important.

Regional Growth and North American Leadership

North America represents a key regional market, supported by the rising prevalence of SBS, increasing surgical interventions, greater disease awareness, early diagnosis, and an established healthcare infrastructure. The United States is particularly important because of its advanced pharmaceutical ecosystem, specialized gastrointestinal care facilities, and growing emphasis on innovative treatment approaches. Europe also presents significant opportunities due to established healthcare systems and increasing attention toward intestinal failure management. Meanwhile, Asia-Pacific is expected to offer long-term opportunities as healthcare infrastructure improves, diagnosis expands, and access to advanced nutritional and pharmaceutical solutions increases. The report covers North America, Europe, Asia-Pacific, South and Central America, and the Middle East and Africa.

Competitive Landscape and Top Players

Takeda Pharmaceutical Company Limited
Zealand Pharma A/S
VectivBio AG,
9 Meters Biopharma, Inc,
Hanmi Pharm.Co.,Ltd,
GlaxoSmithKline, Plc,
Cadila, Pharmaceuticals,
Sun Pharmaceutical Industries Ltd
Troikaa
AJANTA PHARMA

Future Opportunities in Intestinal Regeneration

Intestinal regeneration represents a promising long-term opportunity. Research into stem cells, tissue engineering, gene editing, and regenerative medicine could eventually support approaches that improve intestinal function and reduce long-term dependence on nutritional support. Continued development of GLP-2 analogs and other biologic therapies is also expanding the therapeutic landscape. Although regenerative approaches remain an evolving area, advances in biotechnology could create new treatment paradigms and open additional commercial opportunities for companies investing in SBS research and development.

About US

The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets. Its research combines market sizing, forecasting, competitive analysis, regional assessment, strategic insights, and industry trends to support informed business decisions.

Contact Us

Contact Person: Ankit Mathur

E-mail:ankit.mathur@theinsightpartners.com

Phone: +1-646-491-9876

Also Available in : Korean German Japanese French Chinese Italian Spanish

North America Short Bowel Syndrome Market Outlook 2026-2034: Growth Drivers, Challenges, and Competi

The global short bowel syndrome market size is projected to reach US$ 2.66 billion by 2034 from US$ 1.69 billion in 2025.